Learn why stocks have negative price-to-earnings (P/E) ratios and how to interpret them when evaluating investment ...

Non-GBM Product Revenue Expectation -- Expected contribution of $15-$25 million in 2026, compared to $10 million in 2025, ...

A battery's positive end (cathode) and negative end (anode) are two vital components that largely define how well it can ...

Stay on This Page Pinned Feb 24, 2026 at 3:30 PM EST We are updating this story in real time as new information breaks. Stay ...

Trump’s posting of a video portraying Barack and Michelle Obama as apes is one of his more glaring miscalculations, which have given Democrats an opening to halt a steady erosion of support among ...

- Company to hold conference call and webcast at 8:30 a.m. ET today PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage ...

- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in ...

SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of ...

As his first year back in office ends, Trump's job approval is near the lowest it’s ever been across both of his term.

Julia is the associate news editor for Health, where she edits and publishes news articles on trending health and wellness topics. Her work has been featured in The Heights, an independent student ...

Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer 53% ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the TROPION-Breast02 Phase III trial showed DATROWAY ® (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically ...